Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Army Supports Development of Inhalable Melioidosis Countermeasure

by Global Biodefense Staff
May 16, 2014
Gram Negative Burkholderia pseudomallei

Gram-negative Burkholderia pseudomallei bacteria, which was grown on a medium of sheep’s blood agar for 72 hours. Background image credit: Dr. Todd Parker/CDC

The U.S. Army recently announced intentions to award a sole source contract to the University of Kansas (KU) Therapeutic Particles and Biomaterials Laboratory for the formulation of inhalable therapeutic for the treatment of acute pulmonary melioidosis.

The contract is in support of U.S. Army Medical Research Institute of Infectious Disesases (USAMRIID) requirements to develop an inhalable formulation of the antibiotic ceftazidime for an animal study to investigate its therapeutic efficacy against acute pulmonary melioidosis, to include formulation, physicochemical characterization, and accelerated stability testing.

Melioidosis is an infectious disease caused by a Gram-negative bacterium, Burkholderia pseudomallei, found in soil and water. Melioidosis prevails in parts of Southeast Asia, northern Australia, and Central and South America. However, in recent years, cases of melioidosis have been reported in the United States and other areas. The organism can infect any organ system, although the lung is the most common organ affected.

“The University of Kansas, Therapeutic Particles and Biomaterials Lab is the only known existing source capable of fulfilling the Government’s needs to obtain a NanoCluster drug nanoparticle colloid, which is thermodynamically driven into flocculates of drug nanoparticles (NanoClusters),” states the announcement. “The aerodynamic sizes of these flocculates must be customized for optimal delivery into different regions of the lungs.”

The principal investigator from the University of Kansas for the project is Cory Berkland, KU professor of chemical and petroleum engineering and pharmaceutical chemistry.

Tags: AntimicrobialsBurkholderiaUSAMRIID

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC